Evidence map›Paper›PMID 39761654›Full record

ReviewBritish journal of haematology2025

Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype.

Andrea Serafin, Valeria Ruocco, Alessandro Cellini, Francesco Angotzi, Laura Bonaldi, Livio Trentin, Andrea Visentin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrea SerafinHematology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy.
Valeria RuoccoHematology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy.
Alessandro CelliniHematology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy.
Francesco AngotziHematology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy.ORCID https://orcid.org/0000-0001-7835-2573
Laura BonaldiImmunology and Molecular Oncology Unit, Veneto Institute of Oncology, Padova, Italy.
Livio TrentinHematology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy.ORCID https://orcid.org/0000-0003-1222-6149
Andrea VisentinHematology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy.ORCID https://orcid.org/0000-0003-0271-7200

Funding

Associazione Italiana Ricerca sul Cancro IG-24024PRIN PNRR P2022PSMX4
6 · The paper itself

Abstract

Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease characterised by the uncontrolled proliferation of mature lymphocytes. A subset of CLL patients harbouring complex karyotype (CK) presents with poor prognosis and limited treatment options. This review aims to discuss the current understanding of such patient subset, including its molecular landscape, diagnostic approaches, treatment modalities and emerging therapies. Furthermore, it outlines strategies for personalised management to improve clinical outcomes in this challenging patient population.

Indexed as

Abnormal KaryotypeLeukemia, Lymphocytic, Chronic, B-CellDisease ManagementHumansKaryotypePrognosisBTK inhibitorschronic lymphocytic leukaemiacomplex karyotype (CK)high‐CK cytogenetic complexitynovel therapiesvenetoclax

Identifiers

PMID39761654
PMCPMC11886947

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.